Clinical Trial

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate pharmacodynamics (PD) of AZD0780 compared with placebo by assessment of low-density lipoprotein-cholesterol (LDL-C) levels following repeated oral dosing in healthy adults with elevated LDL-C levels.
Protocol Amendment History 2 changes
critical Trial completed 2026-07-08
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-06
Trial Details
NCT Number NCT07423598
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Healthy Participants
Enrollment 40 participants
Start Date 2026-02-24
Primary Completion 2026-06-29 (estimated)
Study Completion 2026-06-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-07